Superworth

Nektar Therapeutics EPS NKTR

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$6.70
Latest quarter, Q2 FY26
−$1.23
Fiscal year 2025
−$10.22

Nektar Therapeutics' earnings per share was −$6.70 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$1.23.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$10.22n/a
FY2024−$8.75n/a
FY2023−$21.90n/a
FY2022−$29.55n/a
FY2021−$42.90n/a
FY2020−$37.35n/a
FY2019−$37.80−170%
FY2018$54.00n/a
FY2017−$9.75n/a
FY2016−$16.50n/a
FY2015−$9.15n/a
FY2014−$6.75n/a
FY2013−$21.00n/a
FY2012−$22.50n/a
FY2011−$17.85n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$1.23n/a−$6.70
Q1 FY26−$1.82n/a−$8.42
Q4 FY25−$1.78−442%−$10.22
Q3 FY25−$1.87n/a−$7.92
Q2 FY25−$2.95n/a−$8.71
Q1 FY25−$3.62n/a−$9.52
Q4 FY24$0.52n/a−$8.75
Q3 FY24−$2.66n/a−$12.57
Q2 FY24−$3.76n/a−$13.51
Q1 FY24−$2.85n/a−$13.80
Q4 FY23−$3.30n/a−$21.90
Q3 FY23−$3.60n/a−$23.40

Against its peers

Companies in Drug Manufacturers - General nearest Nektar Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
NKTRNektar Therapeutics−$6.70
OMEROmeros$1.52
PCRXPacira BioSciences$0.35
ANABAnaptysbio$4.57
AMPHAmphastar Pharmaceuticals$1.70−36% a year
PAHCPhibro Animal Health$2.44+107% a year
ANIPANI Pharmaceuticals$4.70
ABUSArbutus Biopharma$0.78
HRMYHarmony Biosciences$3.09−0% a year
COLLCollegium Pharmaceutical$1.24+19% a year
PBHPrestige Consumer Healthcare$3.57−16% a year
Peer median$2.07

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Nektar Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.